“I’m wishing for the creation of another Teva or another Check Point in healthcare.” Nacht told Reuters, “We are not here to sell out, we are really here to try … and create a big company in the field of bio-med in Israel.”
Israeli life science startups raised $975 million in 2015, and $680 million in the first nine months of 2016, according to the Israel Venture Capital (IVC) Research Center.
Nacht’s stake in Check Point is estimated at $1.8 billion, according to Globes. In 2012 Nacht was ranked the 11th richest person in Israel by “Forbes” which said that Nacht and his then-wife Anat Agmon had an estimated net worth of $2.5 billion. The couple divorced that same year.
Nacht, who co-founded Check Point with Gil Shwed and Shlomo Kramer in 1993, is raising more than $100 million for a new fund. He is investing tens of millions of dollars of his own money with the help of friends and family, in a dozen startups.
In the biotech area, Nacht has already co-founded DayTwo, an Israeli startup which provides personalized nutrition based on the composition of intestinal bacteria, which is unique to each individual.
Nacht has also invested in Regenera Pharma, which developed a drug from plants that prevents nerve damage in degenerative diseases. Regenera’s product is currently undergoing clinical trials for treatment of the rare optic non-arteritic anterior ischemic optic neuropathy (NAION).